JP2015500833A - ノルイボガインのリン酸エステル - Google Patents

ノルイボガインのリン酸エステル Download PDF

Info

Publication number
JP2015500833A
JP2015500833A JP2014545985A JP2014545985A JP2015500833A JP 2015500833 A JP2015500833 A JP 2015500833A JP 2014545985 A JP2014545985 A JP 2014545985A JP 2014545985 A JP2014545985 A JP 2014545985A JP 2015500833 A JP2015500833 A JP 2015500833A
Authority
JP
Japan
Prior art keywords
compound
hydrogen
monophosphate
formula
diphosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014545985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500833A5 (enExample
Inventor
リチャード ディー． グレス，
リチャード ディー． グレス，
ロバート エム． モリアーティ，
ロバート エム． モリアーティ，
Original Assignee
デメレックス， インコーポレイテッド
デメレックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デメレックス， インコーポレイテッド, デメレックス， インコーポレイテッド filed Critical デメレックス， インコーポレイテッド
Publication of JP2015500833A publication Critical patent/JP2015500833A/ja
Publication of JP2015500833A5 publication Critical patent/JP2015500833A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014545985A 2011-12-09 2012-12-04 ノルイボガインのリン酸エステル Pending JP2015500833A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569150P 2011-12-09 2011-12-09
US61/569,150 2011-12-09
PCT/US2012/067799 WO2013085922A1 (en) 2011-12-09 2012-12-04 Phosphate esters of noribogaine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017161035A Division JP2017203047A (ja) 2011-12-09 2017-08-24 ノルイボガインのリン酸エステル

Publications (2)

Publication Number Publication Date
JP2015500833A true JP2015500833A (ja) 2015-01-08
JP2015500833A5 JP2015500833A5 (enExample) 2016-01-28

Family

ID=48574807

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014545985A Pending JP2015500833A (ja) 2011-12-09 2012-12-04 ノルイボガインのリン酸エステル
JP2017161035A Pending JP2017203047A (ja) 2011-12-09 2017-08-24 ノルイボガインのリン酸エステル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017161035A Pending JP2017203047A (ja) 2011-12-09 2017-08-24 ノルイボガインのリン酸エステル

Country Status (5)

Country Link
US (2) US9051343B2 (enExample)
EP (1) EP2788003A4 (enExample)
JP (2) JP2015500833A (enExample)
CA (1) CA2855994A1 (enExample)
WO (1) WO2013085922A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
JP6049615B2 (ja) 2010-07-23 2016-12-21 デマークス・インコーポレイテッドＤｅｍｅｒｘ，Ｉｎｃ． ノリボガイン組成物
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
JP2015500833A (ja) * 2011-12-09 2015-01-08 デメレックス， インコーポレイテッド ノルイボガインのリン酸エステル
WO2013112673A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Synthetic voacangine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) * 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
CA3256416A1 (en) * 2013-03-15 2025-06-21 Demerx Inc Method for noribogaine treatment of addiction in patients on methadone
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
EP3164402A1 (en) * 2014-04-21 2017-05-10 DemeRx, Inc. N-substituted noribogaine prodrugs
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
SI3223906T1 (sl) 2014-11-26 2021-05-31 Demerx, Inc. Postopki in sestavki za povečanje delovanja opioidnih analgetikov z uporabo alkaloidov iz iboge
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3762498A4 (en) 2018-03-08 2022-03-09 New Atlas Biotechnologies LLC PROCESS FOR PRODUCTION OF TRYPTAMINE
KR20220009955A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
EP3747992A1 (en) 2019-06-04 2020-12-09 Medizinische Hochschule Hannover Compositions and process for integrating cells into epithelium
WO2024145462A1 (en) * 2022-12-29 2024-07-04 Atai Therapeutics, Inc. Ibogaine and noribogaine analogs and methods of use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01100188A (ja) * 1987-08-04 1989-04-18 Bristol Myers Co エピポドフイロトキシングルコシド４′−リン酸誘導体
WO1999011250A2 (en) * 1997-09-04 1999-03-11 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
JP2001511776A (ja) * 1997-02-01 2001-08-14 ニューキャッスル ユニバーシティ ベンチャーズ リミテッド キナゾリノン化合物
US6348456B1 (en) * 1994-07-25 2002-02-19 Deborah C. Mash Method of treating chemical dependency in mammals and a composition therefor
JP2007511542A (ja) * 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
WO2010036998A2 (en) * 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
WO2011022772A1 (en) * 2009-08-27 2011-03-03 Bionomics Limited Combination therapy for treating proliferative diseases

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2813873A (en) 1957-11-19 Derivatives of the ibogaine alkaloids
GB841697A (en) 1956-03-22 1960-07-20 Ciba Ltd Analgesic compositions
GB924042A (en) 1959-03-05 1963-04-18 Geigy Ag J R Process for the decarboxylation of alkyl esters of unsaturated, nitrogen-containing carboxylic acids
US3639408A (en) 1967-06-03 1972-02-01 Shionogi & Co Process for the preparation of isoquinuclidine derivatives
US3516989A (en) 1967-10-02 1970-06-23 American Home Prod Intermediates for total synthesis of iboga alkaloids and means of preparation
FR7131M (enExample) 1968-01-31 1969-07-21
US3557126A (en) 1969-08-14 1971-01-19 American Home Prod Derivatives of iboga alkaloids
US3574220A (en) 1969-08-14 1971-04-06 American Home Prod 1,7-methano-1h-1-benzazepin-5(4h)-ones
CA982478A (en) 1971-04-12 1976-01-27 Jerome Berk Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3715361A (en) 1971-10-08 1973-02-06 American Cyanamid Co Acyl derivatives of 10-methoxyibogamine
US3875011A (en) 1972-11-06 1975-04-01 Syva Co Enzyme immunoassays with glucose-6-phosphate dehydrogenase
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
FR2296418B1 (enExample) 1974-12-30 1978-07-21 Anvar
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
CA1188989A (en) 1981-05-21 1985-06-18 Richard R. Scherschlicht Nonapeptide for the treatment of drug withdrawal symptoms
US4604365A (en) 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4499096A (en) 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
ATE95430T1 (de) 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4587243A (en) 1985-07-15 1986-05-06 Lotsof Howard S Rapid method for interrupting the cocaine and amphetamine abuse syndrome
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4857523A (en) 1988-07-18 1989-08-15 Nda International, Inc. Rapid method for attenuating the alcohol dependency syndrome
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
DE4010079A1 (de) 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5026697A (en) 1990-05-30 1991-06-25 Nda International, Inc. Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome
US5152994A (en) 1990-05-31 1992-10-06 Lotsof Howard S Rapid method for interrupting or attenuating poly-drug dependency syndromes
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5283247A (en) 1991-02-06 1994-02-01 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5290784A (en) 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
AU667527B2 (en) 1992-04-10 1996-03-28 Aventis Inc. Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an S-phase or M-phase specific antineoplastic agent
AU4399093A (en) 1992-06-12 1994-01-04 Des-Tyr Dynorphin Partnership Des-tyr dynorphin analogues
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
EP0668764A1 (en) 1992-09-21 1995-08-30 QIN, Bo-yi Methods for identifying and using low/non-addictive opioid analgesics
CN1042895C (zh) 1992-09-23 1999-04-14 曲曰谦 治疗吸毒者戒断综合症及脱瘾的药物组合物
WO1994014490A1 (de) 1992-12-23 1994-07-07 Bernhard Hugemann Verfestigter arzneistoffvorrat für die mechanische erzeugung inhalierbarer wirkstoffpartikel
US5865444A (en) 1994-03-21 1999-02-02 Deere & Company Body leveling suspension including a pivoting arrangement
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5552406A (en) 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
US5591738A (en) 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
EP0859610B1 (en) 1995-08-08 2006-01-11 Albany Medical College Ibogamine congeners
US5760044A (en) 1996-05-16 1998-06-02 Archer; Sydney Method for treating cocaine and amphetamine dependency
US6291675B1 (en) 1996-05-21 2001-09-18 The United States As Represented By The Department Of Health And Human Services Methods of o-demethylation and n-deprotection
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
YU98003A (sh) 2001-06-11 2006-03-03 Biovitrum Ab. Supstituisana sulfonamidna jedinjenja, postupak za njihovu upotrebu kao leka za tretiranje poremećaja cns, gojaznosti i dijabetesa tipa ii
US20030153552A1 (en) 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
US6806291B1 (en) 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
DE602006018565D1 (de) 2005-08-26 2011-01-13 Medical Res Council London Anionisch substituierte 7-Nitroindol Derivate und deren Verwendung
RU2008126391A (ru) 2005-11-30 2010-01-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 1,5-замещенного индол-2-иламида
EP1998766A2 (en) * 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
US9625475B2 (en) * 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US8362007B1 (en) * 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) * 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
JP6049615B2 (ja) 2010-07-23 2016-12-21 デマークス・インコーポレイテッドＤｅｍｅｒｘ，Ｉｎｃ． ノリボガイン組成物
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
BR112014005064A2 (pt) 2011-09-15 2017-04-04 Demerx Inc não solvatos de sal de norigobaína
JP2015500833A (ja) * 2011-12-09 2015-01-08 デメレックス， インコーポレイテッド ノルイボガインのリン酸エステル
US9783535B2 (en) * 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) * 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US20150258104A1 (en) * 2014-03-13 2015-09-17 Demerx, Inc. Use of noribogaine for the treatment of pain

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01100188A (ja) * 1987-08-04 1989-04-18 Bristol Myers Co エピポドフイロトキシングルコシド４′−リン酸誘導体
US6348456B1 (en) * 1994-07-25 2002-02-19 Deborah C. Mash Method of treating chemical dependency in mammals and a composition therefor
JP2001511776A (ja) * 1997-02-01 2001-08-14 ニューキャッスル ユニバーシティ ベンチャーズ リミテッド キナゾリノン化合物
WO1999011250A2 (en) * 1997-09-04 1999-03-11 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
JP2007511542A (ja) * 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
WO2010036998A2 (en) * 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
WO2011022772A1 (en) * 2009-08-27 2011-03-03 Bionomics Limited Combination therapy for treating proliferative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAZAR, S. ET AL.: "Synthesis and biological activity of the phosphate and sulfate esters of naloxone and naltrexone", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 29(1), JPN6016030648, 1994, pages 45 - 53, ISSN: 0003377769 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine

Also Published As

Publication number Publication date
US20160115185A1 (en) 2016-04-28
EP2788003A4 (en) 2015-05-27
EP2788003A1 (en) 2014-10-15
CA2855994A1 (en) 2013-06-13
US20130165414A1 (en) 2013-06-27
JP2017203047A (ja) 2017-11-16
WO2013085922A1 (en) 2013-06-13
US9051343B2 (en) 2015-06-09

Similar Documents

Publication Publication Date Title
JP2017203047A (ja) ノルイボガインのリン酸エステル
JP2017203046A (ja) ノルイボガインの硫酸エステル
US9586954B2 (en) N-substituted noribogaine prodrugs
ES2957159T3 (es) Estimuladores de SGC fusionados bicíclicos
US8741891B1 (en) N-substituted noribogaine prodrugs
ES2879888T3 (es) Compuestos orgánicos y su uso en el tratamiento o prevención de trastornos del sistema nervioso central
US10682354B2 (en) Compositions and methods
AU2021200164B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
TW200404808A (en) Pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds therefor
TWI787260B (zh) 具有新穎的組成物、組合物及其方法之標靶藥物救援
JP2009537517A (ja) ニコチン性アセチルコリン受容体リガンド１０１
JP2006506395A (ja) ＣＮＳ疾患の治療のための、α７ニコチンアゴニスト活性及び５ＨＴ３アンタゴニスト活性を有する化合物
JP2009525979A (ja) ４−アシルアミノピリジン誘導体を介した神経新生
WO2006088193A1 (ja) 抗腫瘍剤
MXPA00012248A (es) Incrementadores de acetilcolina.
KR20090087042A (ko) 알콜 남용, 중독 및 의존증 치료방법
JP2025160326A (ja) 処置方法
CN120365289A (zh) 稠环类化合物、其制备方法及其在医药上的应用
TW202128707A (zh) 稠合四環類衍生物、其製備方法及其在醫藥上的應用
TW201540714A (zh) Ｎ－經取代之降伊波加因鹼（ｎｏｒｉｂｏｇａｉｎｅ）前藥
HK1254300B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170824